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background:  Severe paravalvular regurgitation (PVR) is a predictor of all-cause mortality after transcatheter aortic valve replacement (TAVR). 
Devices used for transcatheter closure of PVR defects are adapted from other indications; long-term outcomes are not known.
Methods:  The study population consisted of all patients from a single institution who underwent transcatheter implantation of a closure device for 
the treatment of severe PVR. Procedural success was defined by deployment of a closure device and immediate reduction in the degree of PVR to 
none or mild as assessed by TEE (transesophageal echocardiogram).
results:  A total of 11 procedures were performed in patients with severe PVR. All were male with mean age 83.6±4 years and mean STS (Society 
of Thoracic Surgeons) score of 10.6%. Table 1 summarizes the procedural details. The mean fluoroscopy time and amount of contrast used was 63.5 
minutes and 110.5 ml respectively. The procedure was successful in 82% (9/11) of the cases however; all-cause mortality rates at 1, 6 and 12 
months were 37.5%, 62% and 75% respectively.
conclusion:  Despite a high procedural success rate, the long-term outcome after transcatheter closure of severe symptomatic PVR with various 
closure devices remains poor.
Table 1: Procedural characteristics of transcatheter closure of PVR.
ID
Annulus size 
(TTE)
(mm)
Valve size (mm)/
Route
Location of PVR
Days after 
TAVR
Closure 
device
Guiding 
catheter
Device 
size
Degree of PVR 
post-closure
Days of 
follow-up 
after PVR 
closure
Status 
at final 
follow-up
1 21 26/TA Anterior/Posterior 30 VP2 AL2 6F 6mm Mild 10 Dead
2 23 26/TA Anterior 55 VP2 AL2 6F 12mm Mild 290 Dead
3 23 26/TA Posterior 86
Azur Terumo 
Coil
AL2 6F 15mm Moderate 290 Dead
4 23 26/TA Posterior 177 VSD AL1 6F 8mm Mild 290 Dead
5 21 23/TA Anterior/Posterior 3 VSD AL2 6F 10mm Mild 7 Dead
6* 21 26/TF Anterior/Posterior 43 VP2 AL2 4F 12mm Mild 34 Dead
7* 23 26/TF Concentric and Central 253 VSD AL1 6F 10mm Mild 151
Alive, 
NYHA II
8* 21 26/TF Anterior 142 VP2 AL2 6F 12mm Mild 35 Dead
9* 21 26/TA Posterior 177 Δ Δ Δ Mild 35 Dead
10 23 26/TF Posterior 17 VSD AL3 6F 8mm Mild 6 Dead
11 24 26/TF Anterior/Posterior 607 VP2 AL2 6F 6mm Mild 30
Alive, 
NYHA II
TA: Transapical, TF: Transfemoral, *: Also underwent valve in valve, VP: Vascular Plug, VSD: Ventricular septal defect occluder, Δ: (unable to cross the 
leak).
